Aytu biopharma expands and extends lending agreement with eclipse following agreement to commercialize first-in-class antidepressant exxua(tm)

Term loan maturity extended by 12 months to june 2029 principal balance on term loan expanded to $13.0 million from $11.1 million currently expanded revolving line of credit facility by $1.5 million expanded facilities allow for added working capital flexibility as commercial launch of exxua is anticipated to occur in the fourth calendar quarter of 2025 denver, co / access newswire / june 23, 2025 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced it has successfully expanded and extended its lending agreement with eclipse business capital llc ("eclipse"), providing added working capital flexibility as the company prepares for the commercial launch of exxua™ (gepirone) extended-release tablets ("exxua"). gepirone is a new chemical entity, and exxua is the first-in-class selective serotonin 5ht1a receptor agonist approved by the united states food and drug administration ("fda") for the treatment of major depressive disorder ("mdd") in adults.
AYTU Ratings Summary
AYTU Quant Ranking